AtriCure, Inc. (ATRC): Price and Financial Metrics

AtriCure, Inc. (ATRC)

Today's Latest Price: $37.96 USD

0.32 (-0.84%)

Updated Oct 23 6:55pm

Add ATRC to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 142 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

ATRC Stock Summary

  • ATRC's price/sales ratio is 8.05; that's higher than the P/S ratio of 83.71% of US stocks.
  • With a year-over-year growth in debt of 59.62%, AtriCure Inc's debt growth rate surpasses 81.98% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, AtriCure Inc is reporting a growth rate of 184.05%; that's higher than 93.04% of US stocks.
  • Stocks that are quantitatively similar to ATRC, based on their financial statements, market capitalization, and price volatility, are OMCL, ASPN, QTRX, TWOU, and PLAB.
  • ATRC's SEC filings can be seen here. And to visit AtriCure Inc's official web site, go to

ATRC Stock Price Chart Interactive Chart >

Price chart for ATRC

ATRC Price/Volume Stats

Current price $37.96 52-week high $51.76
Prev. close $38.28 52-week low $23.17
Day low $37.50 Volume 138,200
Day high $39.45 Avg. volume 407,238
50-day MA $40.62 Dividend yield N/A
200-day MA $40.80 Market Cap 1.71B

AtriCure, Inc. (ATRC) Company Bio

Atricure provides atrial fibrillation solutions worldwide. The Company has three primary product lines for cardiac tissue ablation and a product line for left atrial appendage exclusion. The company was founded in 2000 and is based in West Chester, Ohio.

ATRC Latest News Stream

Event/Time News Detail
Loading, please wait...

ATRC Latest Social Stream

Loading social stream, please wait...

View Full ATRC Social Stream

Latest ATRC News From Around the Web

Below are the latest news stories about AtriCure Inc that investors may wish to consider to help them evaluate ATRC as an investment opportunity.

AtriCure down 9% on Kerrisdale short call

Thinly traded AtriCure ([[ATRC]] -9.4%) is under modest pressure out of the gate this morning on the heels of a bearish report from Kerrisdale Capital Management who believes its growth drivers face headwinds. Key points:The company's Convergent procedure is unlikely to gain traction considering its poor safety profile and lack...

Seeking Alpha | September 30, 2020

Kerrisdale: AtriCure Inc. (ATRC) Revenue Growth is Set to Short-Circuit

Kerrisdale Capital is short shares of AtriCure, Inc. Q2 2020 hedge fund letters, conferences and more We are short shares of AtriCure, a $1.9bn medical device company that manufactures and sells ablation equipment used in the surgical treatment of atrial fibrillation (AF). At about 7x forward revenues, AtriCure’s valuation implies that the company’s outlook is […] The post Kerrisdale: AtriCure Inc. (ATRC) Revenue Growth is Set to Short-Circuit appeared first on ValueWalk .

ValueWalk | September 30, 2020

AtriCure: Steady Growth, Lackluster Margins

AtriCure (ATRC) is a company not well-covered on this platform. Early 2017, I last reviewed the investment outlook for the shares as I concluded that management would need to find a cure for continued losses. Steady revenue growth and expectations of investors that the business would become profitable have been...

The Value Investor on Seeking Alpha | September 18, 2020

AtriCure to Participate at the Morgan Stanley 18th Annual Global Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Morgan Stanley 18th Annual Global Healthcare Conference being held virtually. AtriCure’s management is scheduled to present on Monday, September 14, 2020, at 2:15 p.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by vi

Business Wire | September 1, 2020

AtriCure Announces Angie Wirick as Chief Financial Officer

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the position of Chief Financial Officer (CFO) for personal reasons and moving into an advisory role through March 5, 2021. Angie Wirick, current Vice President of Finance, has been promoted to CFO effective immediately. “On behalf of our team at AtriCure and our Board of Dire

Business Wire | August 6, 2020

Read More 'ATRC' Stories Here

ATRC Price Returns

1-mo -5.27%
3-mo -15.02%
6-mo -8.29%
1-year 42.76%
3-year 74.05%
5-year 102.13%
YTD 16.76%
2019 6.24%
2018 67.76%
2017 -6.80%
2016 -12.79%
2015 12.42%

Continue Researching ATRC

Here are a few links from around the web to help you further your research on AtriCure Inc's stock as an investment opportunity:

AtriCure Inc (ATRC) Stock Price | Nasdaq
AtriCure Inc (ATRC) Stock Quote, History and News - Yahoo Finance
AtriCure Inc (ATRC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7657 seconds.